Alastair J S Webb1, Sarah T Pendlebury1, Linxin Li1, Michela Simoni1, Nicola Lovett1, Ziyah Mehta1, Peter M Rothwell2. 1. From the Stroke Prevention Research Unit, Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom. 2. From the Stroke Prevention Research Unit, Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom. peter.rothwell@ndcn.ox.ac.uk.
Abstract
BACKGROUND AND PURPOSE: Lack of reduced cognitive impairment with blood pressure (BP) lowering in trials may reflect use of the Mini-Mental State Examination (MMSE), which is insensitive to mild cognitive impairment after cerebrovascular events compared with the Montreal Cognitive Assessment. We determined relationships between impairment on MMSE versus Montreal Cognitive Assessment (MoCA) with the major physiological determinant of vascular cognitive impairment: hypertension and hypertensive arteriopathy. METHODS: Cognitive impairment in consecutive patients 6 months after transient ischemic attack or minor stroke was defined as significant, mild, or none (MMSE<23, 23-26, ≥27; MoCA<20, 20-24, ≥25) and related to 20 premorbid systolic BP readings, home BP measurement (3 measurements, 3×daily for 1 month), and hypertensive arteriopathy (creatinine, stroke versus transient ischemic attack, leukoaraiosis) by ordinal regression. RESULTS: Of 463 patients, 45% versus 28% had at least mild cognitive impairment on the MoCA versus MMSE (P<0.001). Hypertensive arteriopathy was more strongly associated with cognitive impairment on the MoCA than MMSE (creatinine: odds ratio=3.99; 95% confidence interval, 2.06-7.73 versus 2.16, 1.08-4.33; event: 1.53, 1.06-2.19 versus 1.23, 0.81-1.85; leukoaraiosis: 2.09, 1.42-3.06 versus 1.34, 0.87-2.07). Premorbid and home BP measurement systolic BP were more strongly associated with impairment on vascular subdomains of the MoCA than MMSE (odds ratio/10 mm Hg: visuospatial 1.29 versus 1.05; attention 1.18 versus 1.07; language 1.22 versus 0.91; naming 1.07 versus 0.86). CONCLUSIONS: The stronger relationship between impairment on the MoCA with hypertensive arteriopathy, independent of age, indicates a greater sensitivity for vascular-origin cognitive impairment. Use of MoCA should improve sensitivity for cognitive impairment and treatment effects in future studies.
BACKGROUND AND PURPOSE: Lack of reduced cognitive impairment with blood pressure (BP) lowering in trials may reflect use of the Mini-Mental State Examination (MMSE), which is insensitive to mild cognitive impairment after cerebrovascular events compared with the Montreal Cognitive Assessment. We determined relationships between impairment on MMSE versus Montreal Cognitive Assessment (MoCA) with the major physiological determinant of vascular cognitive impairment: hypertension and hypertensive arteriopathy. METHODS: Cognitive impairment in consecutive patients 6 months after transient ischemic attack or minor stroke was defined as significant, mild, or none (MMSE<23, 23-26, ≥27; MoCA<20, 20-24, ≥25) and related to 20 premorbid systolic BP readings, home BP measurement (3 measurements, 3×daily for 1 month), and hypertensive arteriopathy (creatinine, stroke versus transient ischemic attack, leukoaraiosis) by ordinal regression. RESULTS: Of 463 patients, 45% versus 28% had at least mild cognitive impairment on the MoCA versus MMSE (P<0.001). Hypertensive arteriopathy was more strongly associated with cognitive impairment on the MoCA than MMSE (creatinine: odds ratio=3.99; 95% confidence interval, 2.06-7.73 versus 2.16, 1.08-4.33; event: 1.53, 1.06-2.19 versus 1.23, 0.81-1.85; leukoaraiosis: 2.09, 1.42-3.06 versus 1.34, 0.87-2.07). Premorbid and home BP measurement systolic BP were more strongly associated with impairment on vascular subdomains of the MoCA than MMSE (odds ratio/10 mm Hg: visuospatial 1.29 versus 1.05; attention 1.18 versus 1.07; language 1.22 versus 0.91; naming 1.07 versus 0.86). CONCLUSIONS: The stronger relationship between impairment on the MoCA with hypertensive arteriopathy, independent of age, indicates a greater sensitivity for vascular-origin cognitive impairment. Use of MoCA should improve sensitivity for cognitive impairment and treatment effects in future studies.
Authors: Anne M Damian; Sandra A Jacobson; Joseph G Hentz; Christine M Belden; Holly A Shill; Marwan N Sabbagh; John N Caviness; Charles H Adler Journal: Dement Geriatr Cogn Disord Date: 2011-01-29 Impact factor: 2.959
Authors: Stephen T Turner; Andrew D Rule; Gary L Schwartz; Iftikhar J Kullo; Thomas H Mosley; Clifford R Jack; Sharon L R Kardia; Eric Boerwinkle; Kent R Bailey Journal: J Hypertens Date: 2011-09 Impact factor: 4.844
Authors: A Verdelho; S Madureira; C Moleiro; J M Ferro; C O Santos; T Erkinjuntti; L Pantoni; F Fazekas; M Visser; G Waldemar; A Wallin; M Hennerici; D Inzitari Journal: Neurology Date: 2010-07-13 Impact factor: 9.910
Authors: F Forette; M L Seux; J A Staessen; L Thijs; W H Birkenhäger; M R Babarskiene; S Babeanu; A Bossini; B Gil-Extremera; X Girerd; T Laks; E Lilov; V Moisseyev; J Tuomilehto; H Vanhanen; J Webster; Y Yodfat; R Fagard Journal: Lancet Date: 1998-10-24 Impact factor: 79.321
Authors: Phyo Kyaw Myint; Yoon K Loke; William Davison; Katharina Mattishent; George Christopher Fox; Robert Fleetcroft; David Turner; Lee Shepstone; John F Potter Journal: BMJ Open Date: 2017-11-28 Impact factor: 2.692
Authors: Lynne V Gauthier; Chelsea Kane; Alexandra Borstad; Nancy Strahl; Gitendra Uswatte; Edward Taub; David Morris; Alli Hall; Melissa Arakelian; Victor Mark Journal: BMC Neurol Date: 2017-06-08 Impact factor: 2.474
Authors: Sara Mazzucco; Linxin Li; Maria A Tuna; Sarah T Pendlebury; Rhoda Frost; Rose Wharton; Peter M Rothwell Journal: Cerebrovasc Dis Date: 2017-03-21 Impact factor: 2.762
Authors: William J Davison; Phyo K Myint; Yoon K Loke; Garth Ravenhill; David Turner; Chris Fox; Lee Shepstone; John F Potter Journal: BMC Geriatr Date: 2020-09-17 Impact factor: 3.921